Thursday August 18, 2022
  • |Subscribe
  • |Contribute
  • |About
  • |Access Your Account
  • |Register
  • |Login
  • |Home
  • |Issue Archive
    • |Featured Reports
    • |eBooks
  • |BioProcess Insider
  • |Multimedia
    • |BPI White Papers
    • |Webinars
    • |Posters
  • |BioProcess International Events
    • |BioProcess International US West
    • |BioProcess International Europe
  • |BioProcess International Academy
  • |Events

BioProcess International

Covering the whole development process for the global biotechnology industry

  • Upstream
    Processing
    Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies.
    • Assays
    • Biochemicals/Raw Materials
    • Bioreactors
    • Cell Culture Media
    • Expression Platforms
    • Fermentation
    • Perfusion Cell Culture
    • Upstream Contract Services
    • Upstream Single-Use Technologies
  • Downstream
    Processing
    Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies.
    • Filtration
    • Separation/Purification
    • Viral Clearance
    • Chromatography
    • Downstream Contract Services
    • Downstream Single-Use Technologies
  • Manufacturing
    Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting.
    • Personalized Medicine
    • Single Use
    • Supply Chain
    • Vaccines
    • MAb
    • Biosimilars
    • Cell/Gene Therapies
    • Emerging Therapeutics
    • Facility Design/Engineering
    • Continuous Bioprocessing
    • Fill/Finish
    • Formulation
    • Information Technology
    • Manufacturing Contract Services
    • Process Monitoring and Controls
  • Analytical
    Many technologies are used to characterize biological products, manufacturing processes, and raw materials. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion.
    • Culture Development
    • Cell Line Development
    • Downstream Development
    • Downstream Validation
    • Laboratory Equipment
    • PAT
    • Pre-Formulation
    • Product Characterization
    • QA/QC
    • Upstream Development
    • Upstream Validation
    • Leachables/Extractables/Particulates
  • Business
    Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment.
    • Careers
    • CMC Forums
    • Economics
    • Intellectual Property
    • Pre-Clinical and Clinical Trials
    • Regulatory Affairs
    • Risk Management
    • BioRegions

A New Generation of Generic HCP Assays

by BPI Contributor Monday, May 5, 2014  9:01 am

A New Generation of Generic HCP Assays

← Older Post

Editor’s Choice

  • BioProcess Insider

    Flu has no off-season when it comes to manufacturing, says CSL Seqirus

  • BioProcess Insider

    Regenxbio: Inhouse facility a driving force in ‘5×25’ gene therapy ambition

  • Sponsored Content

    Host Cell Protein Analysis: Immunoassays and Orthogonal Characterization By Antibody Affinity Extraction and Mass Spectrometry Methods

  • BioProcess Insider

    Thermo Fisher shells out $76m to expand NY cell culture media site

  • BioProcess Insider

    Core Biogenesis bags $10.5m funding to drive plant-based bioproduction

  • Sponsored Content

    Optimizing Bulk Drug Substance Storage and Shipment: Key Considerations for Rigid Container Design

BioProcess Insider News and Analysis

Recent Tweets

  • Tweet Avatar RT @Dan5tanton: Two co-founders of Taiwanese firm JHL Biotech were sentenced last month for plotting to steal trade secrets from Ge… https://t.co/0iclK4yS7h 4 months ago
  • Tweet Avatar RT @frankvinluan: Shutdown comes 8 months after FDA sent a warning letter about a #microbiome metabolic therapy the #biotech was test… https://t.co/FgtTS54Yj0 4 months ago
  • Tweet Avatar RT @Dan5tanton: A win for CDMO Catalent as it further strengthens its global network, but potentially a loss to the UK taxpayer, wh… https://t.co/Ex9CNdbcf0 4 months ago
  • Tweet Avatar RT @Dan5tanton: The US Department of Health and Human Services #HHS has terminated a long-term #CDMO partnership with Emergent BioS… https://t.co/bAbKWb3uqQ 9 months ago
Follow @bioproinsider

Explore Topics

  • Upstream Processing
  • Downstream Processing
  • Manufacturing
  • Analytical
  • Business

Publication

  • Issue Archive
  • Featured Reports
  • eBooks
  • Subscribe
Connect
Privacy policy

BioProcessIntl.com

  • White Papers
  • Posters
  • Webinars
  • BPI Theater
  • Awards
  • Register
  • Login
  • Access Your Account

Keep up with BPI

  • Email Newsletters
  • Events
  • BioProcess Insider
  • Twitter
  • LinkedIn

About BPI

  • Who We Are
  • Editorial Advisors
  • Author Guidelines
  • Advertising/Media Kit
  • List Rental/Reprints
  • Contact Us
  • Careers
BPI
twitter linkedin
Site Map|Contact
©2022 BioProcess International All Rights reserved
  • Home
  • Issue Archive
    â–¼
    • Featured Reports
    • eBooks
  • BioProcess Insider
  • Multimedia
    â–¼
    • BPI White Papers
    • Webinars
    • Posters
  • BioProcess International Events
    â–¼
    • BioProcess International US West
    • BioProcess International Europe
  • BioProcess International Academy
  • Events